Use of interferon beta for acute respiratory distress syndrome: proceed with caution--authors' reply.
Department of Medicine, University College London and NIHR University College London Hospitals Biomedical Research Centre, UK.
Geoff
G
Bellingan
Department of Medicine, University College London and NIHR University College London Hospitals Biomedical Research Centre, UK; Whittington Hospital London, UK.
Hugh
H
Montgomery
Faron Pharmaceuticals, Turku, Finland.
Mikael
M
Maksimow
MediCity Research Laboratory, University of Turku, Tykistökatu 6 A, 20520, Turku, Finland.
Marko
M
Salmi
MediCity Research Laboratory, University of Turku, Tykistökatu 6 A, 20520, Turku, Finland. Electronic address: sirpa.jalkanen@utu.fi.
Sirpa
S
Jalkanen
D015720:5'-Nucleotidase / Q000378:metabolism*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008168:Lung / Q000378:metabolism*; D008297:Male; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000378:metabolism*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D015720:5'-Nucleotidase